LifeSciences BC > News > Member Announcements

Print Friendly

BC Science Fair Students Win International Awards in Taiwan!

February 14, 2017
Science Fair Foundation of British Columbia

Vancouver, BC – Olivia Li, a Grade 11 student from Earl Marriott Secondary School in Surrey and Elizabeth Schulz, a Grade 12 student from Fraser Lake Elementary Secondary have returned with success from the Taiwan International Science Fair, held February 5 to 11, 2017. Ms. Li received a Bronze Medal in the Microbiology category for … Continue reading BC Science Fair Students Win International Awards in Taiwan!

Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch

February 14, 2017
Aequus Pharmaceuticals Inc.

Vancouver, BC. February 14, 2017 – Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has completed the treatment phase of its multi-dose Proof of Concept clinical trial evaluating the bioavailability and safety of its … Continue reading Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results

February 14, 2017
DelMar Pharmaceuticals Inc.

Company will host a business update conference call and webcast on Wednesday, February 15, 2017 at 4:30 PM EST VANCOUVER, British Columbia and MENLO PARK, Calif., Feb.13, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced its … Continue reading DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results

DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

February 14, 2017
DelMar Pharmaceuticals Inc.

Study is currently enrolling MGMT-unmethylated Avastin (bevacizumab)-naïve recurrent GBM patients at the University of Texas MD Anderson Cancer Center VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 13, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” and the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today … Continue reading DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

Arbutus to Participate in Upcoming Investor Conferences

February 9, 2017
Arbutus Biopharma

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 09, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in upcoming investor conferences. • LEERINK Partners 6th Annual Global Healthcare Conference, February 15-16, 2017, New York• 2017 Disruptive Growth & Healthcare … Continue reading Arbutus to Participate in Upcoming Investor Conferences

Conquer Mobile Wins Best in Show Award at IMSH2017 International Healthcare Simulation Conference with PeriopSim Virtual Reality Training for Nurses

February 9, 2017
Conquer Mobile

Conquer Mobile was awarded ‘Best in Show” at the International Meeting on Simulation in Healthcare (IMSH) Serious Games and Virtual Environments Showcase in Orlando last week. The company won the small company / entrepreneurial award for its PeriopSim Virtual Reality training for OR nurses. Vancouver, BC (PRWEB) – February 7, 2017 – Conquer Mobile today … Continue reading Conquer Mobile Wins Best in Show Award at IMSH2017 International Healthcare Simulation Conference with PeriopSim Virtual Reality Training for Nurses

Aquinox to Present at Leerink Partners 6th Annual Global Healthcare Conference

February 9, 2017
Aquinox Pharmaceuticals, Inc.

VANCOUVER, British Columbia, Feb. 09, 2017 (GLOBE NEWSWIRE) — Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, President & CEO, will provide a corporate update at the upcoming Leerink Partners 6th Annual Global Healthcare Conference in New … Continue reading Aquinox to Present at Leerink Partners 6th Annual Global Healthcare Conference

Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology

February 8, 2017
Arbutus Biopharma Corp.

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced that the Supreme Court of British Columbia granted Arbutus’ request for a pre-trial injunction against Acuitas, preventing Acuitas from sublicensing … Continue reading Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology

LifeSciences BC Hires New Executive Director

February 2, 2017
LifeSciences BC

Vancouver, B.C. – February 2, 2017 – The LifeSciences BC’s Board of Directors is pleased to announce the appointment of Dr. Lesley Esford, as the new Executive Director of the non-profit industry association. Since 2006, Esford has worked as an ITA with the National Research Council – Industrial Research Assistance Program, helping over 100 entrepreneurs … Continue reading LifeSciences BC Hires New Executive Director

The Centre for Drug Research and Development (CDRD) Appoints Gordon McCauley as President and CEO

February 2, 2017
The Centre for Drug Research and Development

February 1, 2017 – Vancouver, Canada – The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization centre, is pleased to announce that, following a global executive search, it has appointed Gordon McCauley as its President and CEO. A Vancouver-based life sciences leader with international experience in the industry, Mr. McCauley … Continue reading The Centre for Drug Research and Development (CDRD) Appoints Gordon McCauley as President and CEO